Bioterrorism: class A agents and their potential presentations in immunocompromised patients
- PMID: 18390465
- DOI: 10.1188/08.CJON.295-302
Bioterrorism: class A agents and their potential presentations in immunocompromised patients
Abstract
A bioterrorism attack would be particularly challenging for medical professionals caring for patients with cancer who often have weakened immune systems. Knowledge of the class A agents and the potential variable presentations in immunocompromised patients is key to early recognition of an outbreak and prompt reporting. The purpose of this article is to present the class A agents: Bacillus anthracis (anthrax), botulinum toxin (botulism), variola virus (smallpox), Yersinia pestis (pneumonic plague), and Francisella tularensis (tularemia). The variable signs and symptoms that may be present in immunocompromised patients with cancer will be discussed with a focus on assessment and early recognition of an outbreak. The availability of vaccines and the implications for patients with cancer receiving these vaccines also will be discussed.
Similar articles
-
Bioterrorism's invisible threats: heightened awareness will help nurses identify real and suspected bioterrorism.Nurs Manage. 2002 Jan;33(1):43, 45-7. Nurs Manage. 2002. PMID: 11984331
-
Molecular diagnostic techniques for use in response to bioterrorism.Expert Rev Mol Diagn. 2003 Sep;3(5):605-16. doi: 10.1586/14737159.3.5.605. Expert Rev Mol Diagn. 2003. PMID: 14510181 Review.
-
[Bioterrorism].Nihon Hoigaku Zasshi. 2005 Oct;59(2):119-25. Nihon Hoigaku Zasshi. 2005. PMID: 16296383 Review. Japanese.
-
Oncology nursing implications related to smallpox bioterrorism preparations.Clin J Oncol Nurs. 2004 Feb;8(1):51-5. doi: 10.1188/04.CJON.51-55. Clin J Oncol Nurs. 2004. PMID: 14983764 Review.
-
Ability of physicians to diagnose and manage illness due to category A bioterrorism agents.Arch Intern Med. 2005 Sep 26;165(17):2002-6. doi: 10.1001/archinte.165.17.2002. Arch Intern Med. 2005. PMID: 16186470
Cited by
-
Structure of the Yersinia pestis FabV enoyl-ACP reductase and its interaction with two 2-pyridone inhibitors.Structure. 2012 Jan 11;20(1):89-100. doi: 10.1016/j.str.2011.07.019. Structure. 2012. PMID: 22244758 Free PMC article.
-
Fever and Rash: A Changing Landscape in the 21st Century.Clin Pediatr Emerg Med. 2008 Dec;9(4):244-249. doi: 10.1016/j.cpem.2008.09.008. Epub 2008 Nov 20. Clin Pediatr Emerg Med. 2008. PMID: 32288649 Free PMC article.
-
Selectivity of Pyridone- and Diphenyl Ether-Based Inhibitors for the Yersinia pestis FabV Enoyl-ACP Reductase.Biochemistry. 2016 May 31;55(21):2992-3006. doi: 10.1021/acs.biochem.5b01301. Epub 2016 May 17. Biochemistry. 2016. PMID: 27136302 Free PMC article.
-
Detoxified endotoxin vaccine (J5dLPS/OMP) protects mice against lethal respiratory challenge with Francisella tularensis SchuS4.Vaccine. 2010 Apr 1;28(16):2908-15. doi: 10.1016/j.vaccine.2010.01.067. Epub 2010 Feb 17. Vaccine. 2010. PMID: 20170768 Free PMC article.
-
Establishment of the black-tailed prairie dog (Cynomys ludovicianus) as a novel animal model for comparing smallpox vaccines administered preexposure in both high- and low-dose monkeypox virus challenges.J Virol. 2011 Aug;85(15):7683-98. doi: 10.1128/JVI.02174-10. Epub 2011 Jun 1. J Virol. 2011. PMID: 21632764 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical